Altimmune Inc logo

ALT

Altimmune Inc

$17.24

Earnings Summary

Revenue
$0.03Mn
Net Profits
$-19.43Mn
Net Profit Margins
-60718.75%

Highlights

Revenue:

Altimmune Inc’s revenue fell -96.18% since last year same period to $0.03Mn in the Q1 2022. On a quarterly growth basis, Altimmune Inc has generated 102.84% jump in its revenue since last 3-months.

Net Profits:

Altimmune Inc’s net profit fell -30.72% since last year same period to $-19.43Mn in the Q1 2022. On a quarterly growth basis, Altimmune Inc has generated -126.58% fall in its net profits since last 3-months.

Net Profit Margins:

Altimmune Inc’s net profit margin fell -3321.19% since last year same period to -60718.75% in the Q1 2022. On a quarterly growth basis, Altimmune Inc has generated -837.13% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Altimmune Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.47
EPS Estimate Current Year
-0.47

Highlights

EPS Estimate Current Quarter:

Altimmune Inc’s earning per share (EPS) estimates for the current quarter stand at -0.47 - a 18.97% jump from last quarter’s estimates.

EPS Estimate Current Year:

Altimmune Inc’s earning per share (EPS) estimates for the current year stand at -0.47.

Key Ratios

Key ratios of the Altimmune Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.44
Return on Assets (ROA)
-0.25
Return on Equity (ROE)
-0.44
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Altimmune Inc’s earning per share (EPS) fell -15.79% since last year same period to -0.44 in the Q1 2022. This indicates that the Altimmune Inc has generated -15.79% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Altimmune Inc’s return on assets (ROA) stands at -0.25.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Altimmune Inc’s return on equity (ROE) stands at -0.44.

Dividend Per Share (DPS):

Altimmune Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.58
-0.44
24.14%

Company Information

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).

Organisation
Altimmune Inc
Headquarters
910 Clopper Road, Gaithersburg, MD, United States, 20878
Employees
43
Industry
Commercial Services
CEO
Vipin Garg